KCM
JANX icon

Kennedy Capital Management’s Janux Therapeutics JANX Stock Holding History

Kennedy Capital Management’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,413
Closed -$279K – 563
2025
Q3 		$279K Buy
11,413
+1,905
+20% +$46.4K 0.01% 542
2025
Q2 		$220K Sell
9,508
-7,093
-43% -$187K 0.01% 564
2025
Q1 		$448K Buy
16,601
+3,888
+31% +$147K 0.01% 588
2024
Q4 		$681K Buy
12,713
+928
+8% +$49.1K 0.02% 623
2024
Q3 		$535K Buy
11,785
+1,805
+18% +$78.5K 0.01% 633
2024
Q2 		$418K Buy
+9,980
New +$469K 0.01% 646

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Kennedy Capital Management's JANX Position: Q4 2025 in Review

Kennedy Capital Management sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 11,413 shares — an estimated $279K sold.

Kennedy Capital Management first reported a position in JANX in Q2 2024 and held it in 6 quarters. The position peaked at $681K in Q4 2024. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Kennedy Capital Management reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Kennedy Capital Management sold 11,413 Janux Therapeutics shares in Q4 2025, an estimated $279K.
  • Kennedy Capital Management first reported a position in Janux Therapeutics in Q2 2024 and held it in 6 quarters.
  • Kennedy Capital Management's Janux Therapeutics position peaked at $681K in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Kennedy Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.